Kura Oncology legal chief sells 8,601 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. Chief Legal Officer Teresa Brophy Bair sold 8,601 shares of common stock at $7.44 per share on November 16, 2026, under a Rule 10b5-1 trading plan. She held 178,401 shares directly after the sale. The sale covered taxes associated with vesting one-sixth of the underlying shares of performance-based restricted stock units after the one-year anniversary of a specified development milestone was determined to have been met on November 13, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 8,601 | $7.44 | $64K |
Footnotes (1)
- F1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on November 13, 2026, resulting in the vesting of 1/6th of the underlying shares.
Key Figures
Key Terms
Sell-to-cover financial
performance-based restricted stock units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.